AI stock analysis · Biotechnology · Last analyzed Jul 8, 2026
Compass Score
4.0/5
Call
Buy
Price
$5.58
AI Target
$10.00 +79.2%
AI Analyst Summary
Aclaris Therapeutics is a clinical-stage biotech generating 37.2% YoY revenue growth, reflecting early commercial or licensing traction that has attracted near-unanimous analyst bullishness — 10 of 10 analysts rate the stock a Buy with a consensus price target of $10.00, implying roughly 79% upside from current levels. The primary bull thesis rests on pipeline de-risking and accelerating top-line momentum as key programs advance toward data readouts or regulatory milestones. The key risk is the company's loss-making status with a negative forward P/E, leaving it dependent on external financing and highly vulnerable to clinical trial failures or funding disruptions.
Catalysts
Pipeline clinical data readouts that could validate lead drug candidates and serve as near-term re-rating events for the stock.
Continued acceleration of revenue growth beyond 37.2% YoY, potentially driven by licensing deals, partnerships, or early commercial ramp.
Potential analyst price target upgrades or new initiations given the strong Buy consensus, which could increase institutional visibility and buying pressure.
Risks
Loss-making operations with a negative forward P/E of -6.7x create ongoing dilution risk through equity offerings needed to fund the cash burn.
Clinical trial failure in any lead pipeline asset could cause a sharp, potentially irreversible de-rating given the stock's valuation is almost entirely pipeline-dependent.
Below-average EPS beat rate (2 of 4 quarters) signals execution inconsistency; a miss on revenue or cash runway guidance could undermine the strong analyst consensus and trigger downgrades.
Fundamentals
PeN/A (loss-making) · 1.0/5
No trailing P/E available; company is loss-making with a negative forward P/E of -6.7x, indicating no near-term path to profitability. Typical for clinical-stage biotech but a clear valuation red flag.
PegN/A · 3.0/5
PEG ratio is unavailable due to negative earnings. Defaulting to neutral score of 3; strong revenue growth of 37.2% YoY provides some partial offset but cannot substitute for earnings-based PEG analysis.
Analyst RatingStrong Buy consensus (1.09) · 5.0/5
10 Buy ratings and 1 Hold with zero Sell ratings across 10 analysts yields an implied consensus of ~1.09 — firmly in Strong Buy territory. Broad and uniform bullish conviction supports a score of 5.
No meaningful earnings trend due to ongoing losses. However, 37.2% YoY revenue growth signals commercial or pipeline traction. EPS beat rate of 2 of 4 quarters is below average. Score reflects loss-stage status tempered by solid top-line momentum.
Price Target Beat2 of 4 quarters beat · 2.0/5
EPS beat rate of 2 out of 4 recent quarters is below average, suggesting inconsistent execution against consensus estimates. Only 4 quarters of data available, limiting confidence in the assessment.
ManagementMixed execution signals · 3.0/5
Strong analyst conviction (10 of 10 bullish) suggests confidence in strategic direction, but below-average EPS beat rate of 2 of 4 quarters points to inconsistent near-term execution. Capital allocation in a loss-making biotech carries inherent uncertainty. Neutral score is appropriate.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.